Aptorum Group (APM) AI Stock Analysis

• Market Cap: $8.63M
• Dividend Yield: N/A
• Average Volume (3M): 113.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: N/A
• EPS Growth: -1979.68%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 6,346,823
• 10 Day Avg. Volume: 164,850
• 30 Day Avg. Volume: 113,319
• PEG Ratio: -0.14
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.82
• Enterprise Value/Market Cap: 2.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -71.32
• Enterprise Value/Ebitda: -4.84
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.00 ▼(-6.54% Downside)

The score is driven primarily by weak financial performance (revenue down to $0, ongoing losses, and negative operating/free cash flow). Technicals add pressure with a broad downtrend and negative momentum, while valuation is constrained by a negative P/E and no dividend support. Modest leverage is a partial offset but does not outweigh the cash-burn and shrinking balance-sheet base.

Positive Factors

Strategic Partnership

The merger with DiamiR Biosciences represents a strategic expansion into diagnostics, potentially diversifying revenue streams and leveraging combined expertise for innovation.

Regulatory Approval

Regulatory approval for the APOE Genotyping test enhances Aptorum's market credibility and opens new revenue opportunities in molecular diagnostics.

Debt Management

Improved debt management reflects positively on financial health, reducing financial risk and potentially improving investor confidence in long-term stability.

Negative Factors

Revenue Decline

Persistent revenue decline indicates challenges in market penetration and product adoption, which could hinder long-term growth prospects and operational sustainability.

Negative Cash Flow

Negative cash flow from operations suggests ongoing financial strain, limiting the company's ability to invest in growth initiatives without external financing.

Profitability Challenges

Minimal gross profit margins highlight difficulties in achieving cost efficiency, which may affect the company's ability to achieve sustainable profitability.

Aptorum Group Business Overview & Revenue Model

Company Description

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Aptorum Group generates revenue primarily through the development and commercialization of pharmaceutical products. The company engages in the research and development of novel therapeutics, which, upon reaching successful clinical trial phases and receiving regulatory approvals, are either marketed directly or licensed to larger pharmaceutical companies that handle distribution. Licensing agreements and partnerships with other biotech firms and research institutions are significant contributors to its revenue, allowing Aptorum Group to leverage external expertise and resources to enhance its drug development pipeline. Additionally, Aptorum explores revenue generation through its healthcare consumer products segment, which involves the sale of non-pharmaceutical products that align with its core focus on health and wellness.

Aptorum Group Financial Statement Overview

Summary

Aptorum Group faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. While debt management has improved slightly, the company's profitability and cash generation remain concerning. Continued operational losses and reliance on financing suggest potential liquidity risks.

Income Statement

The company shows declining revenue over the years with a significant revenue drop from 2022 to 2023. Gross profit margins are minimal, indicating challenges in covering costs. Net income remains negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet indicates a reduction in total debt over the recent years, improving the debt-to-equity ratio. However, the equity ratio has decreased due to reducing stockholders' equity, which may indicate financial distress or poor returns on equity investments.

Cash Flow

Cash flow from operations remains negative, indicating cash burn. Free cash flow is consistently negative, suggesting the company struggles to generate cash after expenses. There is some improvement in financing activities, showing reliance on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	431.38K	1.30M	1.54M	911.51K
Gross Profit	-255.00K	10.57K	80.06K	81.85K	-104.00K
EBITDA	-3.76M	-9.48M	-10.32M	-25.83M	6.50M
Net Income	-4.27M	-2.83M	-9.80M	-25.05M	7.07M
Balance Sheet
Total Assets	16.13M	20.64M	20.87M	21.91M	44.23M
Cash, Cash Equivalents and Short-Term Investments	874.24K	2.01M	1.99M	8.50M	31.88M
Total Debt	3.35M	3.49M	6.85M	217.17K	3.32M
Total Liabilities	4.35M	5.26M	13.03M	4.40M	6.08M
Stockholders Equity	21.13M	24.85M	15.71M	23.61M	41.83M
Cash Flow
Free Cash Flow	-1.19M	-7.73M	-12.51M	-14.79M	-16.09M
Operating Cash Flow	-1.19M	-7.72M	-12.32M	-14.65M	-15.93M
Investing Cash Flow	58.62K	624.77K	2.44M	16.51M	1.84M
Financing Cash Flow	1.43K	4.09M	6.63M	2.78M	12.42M

Aptorum Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APM, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.10, below the 50-day MA of 1.26, and below the 200-day MA of 1.34, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 39.84 is Neutral, neither overbought nor oversold. The STOCH value of 29.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APM.

Aptorum Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AEON	52 Neutral	$13.41M	0.23	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMNN	48 Neutral	$12.41M	-0.34	-233.50%	―	―	57.97%
DWTX	46 Neutral	$86.21M	-0.11	-97.54%	―	―	-295.27%
APM	42 Neutral	$8.63M	-2.99	-9.02%	―	―	-1979.68%

Aptorum Group Corporate Events

Aptorum Group Secures $2 Million in Direct Offering to Support Merger Plans

On October 10, 2025, Aptorum Group Limited announced a registered direct offering with non-affiliated institutional investors, resulting in gross proceeds of approximately $2 million. The offering, which closed on October 14, 2025, involved the sale of 1,000,000 Class A ordinary shares and restricted warrants to purchase up to 2,000,000 ordinary shares. The proceeds are intended for working capital, general corporate use, and expenses related to a potential merger with DiamiR Biosciences Corp. This strategic financial move is expected to bolster Aptorum’s operational capabilities and support its merger plans, although the merger is contingent on certain conditions.

Aptorum Group Announces Merger with DiamiR Biosciences

Aptorum Group Limited announced a merger agreement with DiamiR Biosciences Corp., which was initially disclosed on July 14, 2025. The merger involves forming a wholly owned subsidiary in Delaware, which will merge with DiamiR, making it a wholly owned subsidiary of Aptorum. This strategic move aims to enhance Aptorum’s capabilities in the biotechnology field, potentially impacting its market positioning and stakeholder interests. The merger is contingent upon shareholder approval and other conditions outlined in the agreement.